Led by renowned cardiologist Dr. Milind Desai, this course is designed to empower healthcare professionals with the knowledge and skills to provide comprehensive and patient-centered care to individuals affected by Hypertrophic Cardiomyopathy (HCM). This program strongly emphasizes enhancing patient access to specialized care and fostering a collaborative, team-based approach to managing this complex cardiac condition.
Explore access considerations for novel HCM treatments, including overcoming challenges related to insurance coverage, treatment availability, and clinical trial participation in this on-demand course. You’ll work through barriers to prescribing novel therapies including prior authorizations and specialty pharmacy considerations, which can be addressed through proactive communication and documentation. Finally, learn from Dr. Desai about adopting a team-based approach to medication administration in different settings to ensure comprehensive patient care and effective monitoring. Also, discover how follow-up echocardiography is crucial for HCM management, helping healthcare providers assess treatment response and identify potential complications.
The discussion is part of a four-part series on HCM. To view other sessions in the series visit:
- Discuss access considerations for novel HCM treatments
- Explain potential barriers and related solutions to prescribing a cardiac myosin inhibitor, including prior authorizations and specialty pharmacy considerations
- Compare team-based approaches for successful medication administration in clinical settings, pharmacies, and home
- List the follow-up echocardiography requirements for HCM management
Non-CE certificate of attendance/participation is available upon submission of the program evaluation.
- Milind Desai, MD, MBA
PCNA is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030602.